Clicky

Hexima Ltd(HXL)

Description: Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is HXP124, which is in a phase IIb clinical trial for the treatment of fungal toenail infections. It operates in the topical antifungal sector of the pharmaceutical product development industry worldwide. The company was founded in 1997 and is headquartered in Melbourne, Australia.


Keywords: Natural Sciences Biotechnology Pharmaceutical Life Sciences Medication Health Care Infection Clinical Trial Peptides Proteins Product Development Peptide Anacor

Home Page: www.hexima.com.au

HXL Technical Analysis

Corporate One
Preston, VIC 3072
Australia
Phone: 61 3 9479 1210


Officers

Name Title
Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. Acting CEO, COO & Exec. Director
Ms. Helen Molloy Financial Controller
Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT Chief Science Officer
Dr. Nancy Sacco Chief Devel. Officer
Ms. Leanne Ralph Company Sec.
Dr. Neil Forrester VP of Bus. Devel.
Prof. Adrienne Elizabeth Clarke Science Advisor

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.8414
Price-to-Sales TTM: 0.6612
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks